Discover the latest resources from Etap-LAB

Contact an expert

Published on the 17 December 2018

ETAP-Lab, 2018 – Newsletter #4

Within the framework of the European project MEDILIGHT, the consortium selected ETAP-Lab to outsource a preclinical study aiming at evaluating the efficacy of a miniaturized smart system built up to i…
Published on the 1 November 2018

Newsletter #3

New ETAP-Lab studies on TEMISIS’ drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced psoriasis model. The output of thes…
Published on the 4 October 2018

Strok@lliance – Newsletter #4

Post-stroke deficits and recovery from bench to patient’s bed This year again, Strok@lliance aimed at bridging the gap between laboratory and clinical practices. The event occured at…
Published on the 1 October 2018

Newsletter #2

ETAP-Lab supports Plant Advanced Technologies in the development of its TEM1657 compound for the treatment of psoriasis TEM1657 is a drug candidate discovered and optimized by Plant Advanced Techno…
Published on the 20 June 2018

Evaluation of the antidepressant- and anxiolytic-like effects of a hydrophilic extract from the green seaweed Ulva sp. in rats

OBJECTIVES: The green seaweed Ulva sp. contains a large amount of ulvans, a family of sulphated polysaccharides. The present study was designed to investigate in rats the antidepressant- and anxiolyti…
Published on the 12 June 2018

Lactobacillus salivarius LA307 and Lactobacillus rhamnosus LA305 attenuate skin inflammation in mice

Oral probiotics potential for the management of dermatological diseases is vast. However, results of available studies in skin diseases, such as atopic dermatitis (AD), are inconsistent, partly becaus…
Published on the 22 May 2018

Strok@lliance – Newsletter #2

2nd Strok@lliance Annual Meeting June 5th, 2018 – 10:00 AM – 4:30 PMMAISON DE LA CHIMIE28 Rue Saint-Dominique, 75007 Parishttp://congres.maisondelachimie.com/ Post-stroke deficits and re…
Published on the 27 February 2018

Strok@lliance – Newsletter #1

Focus on an innovative model of thromboembolic stroke reproducing the clinical situation Recombinant tissue-type plasminogen activator (rt-PA) is the only approved drug treatment at the acute p…